TNFRSF17 and plasma cell myeloma: Preliminary results from an ongoing phase 1 study of an anti-GPRC5D CAR OriCAR-017 (NCT05016778) were recently presented in 9 patients with R/R myeloma, including patients previously treated with anti-BCMA CAR T therapies.